On June 11, Hong Kong stocks trended lower as the robotics and LLM sectors underwent a broad correction, with Alibaba sliding 5.4% amid structural adjustments at DingTalk. Bucking the trend, MININGLAMP-W surged nearly 20% as its Southbound Stock Connect inclusion and Agentic AI positioning continued to attract capital inflows. In key industry dynamics, OpenAI partnered with Oracle to lower enterprise barriers via existing cloud commitments ahead of its IPO; ZHIPU AI and Tsinghua open-sourced the SCAIL-2 character animation model; and tech giants Alibaba, Tencent, and Baidu launched specialized Gaokao planning AI Agents to capture the massive traffic window of 12.9 million candidates.
With this layout in edge-side AI hardware, Mininglamp Technology-W (2718.HK) has achieved a complete hardware-software integrated closed-loop spanning from perception (Octic) to processing (Mano-P) to collaboration (Octo).
NewTimeSpace News: On June 11, 2026, RoboSense(02498.HK) weakened amid fluctuations in the morning session. As of 11:40, the stock traded at HK$28.28, down 5.48%. The company's pending orders for ADAS products have surpassed 9 million units.
NewTimeSpace (newtimespace.com) News, On June 11, 2026, the Hang Seng Tech Index fluctuated during morning trading, while large model concept stocks collectively strengthened. Mininglamp Technology-W (2718.HK) staged a substantial upward surge in the morning session. As of 9:40 AM, the company's share price was quoted at HK$188.00, up 11.51%.
NewTimeSpace News: Kintor Pharmaceutical Limited (09939.HK) announced that the interim results of the long-term human safety trial for its core product KT-939 were positive. None of the 119 subjects experienced any adverse skin reactions after 28 consecutive weeks of use, demonstrating a sound safety profile. Meanwhile, the Company has launched the registration application for KT-939 as a new cosmetic raw material, with relevant technical documents submitted to the National Institutes for Food and Drug Control.
NewTimeSpace News: Hansoh Pharmaceutical Group Company Limited (03692.HK) announced that the New Drug Application (NDA) for its innovative drug HS-10568 Injection (partner code: SHR6508) was accepted by the National Medical Products Administration (NMPA) on June 9, 2026. It is indicated for secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease undergoing hemodialysis. HS-10568 is an allosteric modulator of calcium-sensing receptor (CaSR).
NewTimeSpace News: Shanghai Bao Pharmaceuticals Co., Ltd. (02659.HK) announced that the Investigational New Drug (IND) application for its self-developed subcutaneous infusion ceftriaxone sodium BJ007 has been approved by the U.S. Food and Drug Administration (FDA), authorizing clinical trials. According to Frost & Sullivan, no subcutaneous ceftriaxone sodium has been approved globally, and BJ007 is the first and only candidate drug in its class to enter clinical development.
On June 10, the three major Hong Kong indices drifted lower, with chip and LLM concept stocks under selling pressure as ZHIPU AI slid over 7%, while AI application plays like Kuaishou and Tencent bucked the trend. Internationally, Anthropic released its Fable 5 model with tightened security constraints alongside an unaligned version to ease regulatory oversight ahead of its IPO. Domestically, Meituan officially launched its AI-native browser Tabbit 1.0, enabling automated cross-webpage workflows across multiple LLMs, while Zhipu AI allied with HFUT to establish a multi-tier "LLM Innovation Experimental Class" to secure elite talent pipelines for the industry.
NewTimeSpace News: China International Software issued a voluntary announcement on June 10 for the official launch of allmeta Ontology v1.0, an actionable ontology platform tailored for enterprise AI deployment.
NewTimeSpace News: Baiyunshan announced on June 10 that its subsidiary, Baiyunshan General Pharmaceutical Factory, has received the Drug Registration Certificate for Cefaclor Sustained-release Tablets (II) approved and issued by the National Medical Products Administration.
Mininglamp Technology (2718.HK)'s edge-side AI product matrix, its Mano-P is responsible for the edge-side agent's understanding and decision-making, Cider is responsible for inference acceleration to release hardware computing power, Octo is responsible for multi-Agent collaboration and organization-level orchestration, and Octic is responsible for the data collection entry point of offline scenarios. At present, all four products across the model, engine, collaboration network, and hardware have been either fully open-sourced or officially released.
NewTimeSpace News: Hbm Holdings Limited (02142.HK) announced that the National Medical Products Administration of China has accepted the Investigational New Drug (IND) application for HBM7004, a novel B7H4xCD3 bispecific antibody for the treatment of advanced solid tumors. Previously, the product's IND application was approved by the U.S. FDA, paving the way for its first-in-human Phase I clinical trial.
NewTimeSpace News: As of 13:08 on June 10, 2026, XPENG-W (09868.HK) weakened in the afternoon session, trading at HK$57.90, down 5.55%. Its Robotaxi equipped with VLA2.0 is undergoing L4 autonomous driving tests on public roads in Guangzhou.
NewTimeSpace (newtimespace.com) News: On June 10, 2026, the robotics concept sector in the Hong Kong stock market weakened. UBTECH (09880.HK) dropped substantially during morning trading. As of 11:21 AM, the company's share price was quoted at HK$110.400, down 5.40%.
NewTimeSpace (newtimespace.com) News: On June 10, 2026, Kuaishou-W (01024.HK) surged substantially during morning trading. As of 10:08 AM, the company's share price was quoted at HK$46.060, up 3.88%, leading the gains in the Hang Seng Tech Index.
Newtimespace (newtimespace.com) reports that Antengene (6996.HK) announced the NMPA has approved the IND application for ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell-mediated autoimmune diseases, allowing Phase I studies to proceed; the company plans to rapidly initiate the China Phase I trial while preparing for Australian clinical development, with ATG-201 based on the proprietary AnTenGager® second-generation TCE platform, though the Group does not guarantee its ultimate successful development or commercialization.
